anti-albuminuric effect of 1ow-dose spironolactone in patients with diabetic nephropathy - anti-albuminuric effect of 1ow-dose spironolactone in patients with diabetic nephropathy

The spironolactone group showed a significant reduction in UACR from baseline compared with the control group which showed an increased UACR (p = 0.0007, Wilcoxon rank-sum test and t-test). Although the spironolactone group had a statistically significant increase in serum potassium levels, none of the participants had a potassium level >5.5 mEq/L at 24 weeks. Further, participants with a higher initial serum potassium level tended to have a smaller increase (estimate -0.37, analysis of covariance).